KLRK1 and cancer: While NKG2D is known as an activation marker in HCC (47), and its expression has been observed to be reduced in liver resident NK (lrNK) cells from HCC (24, 25), some reports propose that in advanced cancers driven by inflammation, such as HCC, the expression of NKG2D can drive cancer progression rather than rejection (48, 49)).